



nexus | ag

Quarterly Report

01ST JANUARY TO 30TH SEPTEMBER 2018

Letter to our Stockholders

Dear Stockholders:

The message for the third quarter is simple: We are continuing to grow, increase our profitability and tackle new, future-oriented projects and acquisitions! The NEXUS Team is extremely pleased about this again positive development in the first nine months of the current year.

With a sales increase of approx. 11 % and an increase in earnings before interest and taxes as well as acquisition-related amortization (EBITA) of approx. 17 %, we again were able to combine growth and improved results very successfully. If we take into account the strong prior-year figures, the negative exchange rate developments against the Swiss franc and the high integration costs, the Q3 result is particularly noteworthy.

Even in absolute numbers, we were able to show impressive results in the first nine months: EBITDA increased to approx. EUR 19 million, and our operating cash flow reached approx. EUR 20 million.

The strong development of our business figures in the first nine months is mainly due to our new product generation "NEXUS / NEXT GENERATION". The good market acceptance has been shown in the increasing number of incoming orders and sales figures. In particular, our existing customers

show that we have set a trend with the implementation of a completely user-related and intuitive user interface, which has fully met user expectations. The same applies to the mobile apps, which have recorded a significant increase in sales in the nine months of 2018. Mobility in the use of e-health systems is becoming an increasingly important feature for users, and it is a trend that is motivating hospitals to make additional investments.


Highlights 9 months 2018 Company development

- + Strong development of sales in the first nine months
- + NEXUS / NEXT GENERATION very successful in sales
- + Acquisition (signing) of a leading laboratory software manufacturer
- + Sales successes in Germany, Poland and France

On the order page, we have been able to obtain very interesting new projects in the first nine months. This is especially true for Poland and France, where we received large orders. On the project side, we made significant progress with


Development of Group Sales (9 months) in KEUR

2007-2018



Development of EBITDA (9 months) in KEUR

2007-2018



the major projects Deutsche Rentenversicherung, Hirslanden RIS (CH), St Gallen (CH) and „ENDOBASE NEXT“. We have invested a lot of money in these projects and are now very optimistic about their further development.

We were also able to tackle the known problems in our healthcare service area. The organizational reorganization under the title „Cloud IT“ is showing initial successes, and the legacy issues „Project Delays“ „GDPR“ and „Problems with Recruitment“ are increasingly being solved.

We took a very important step in our product and company development on 11 October 2018 by signing a purchase agreement for the acquisition of Roche Diagnostics IT Solutions GmbH, Berlin, with the associated laboratory products „SWISSLAB Laboratory Information System“ and „LAURIS Order Communication System“. The products close the last major product gaps in our portfolio.

Under the ownership of Roche, the products „SWISSLAB“ and „LAURIS“ were developed into a leading laboratory solution in Germany and Austria and expansion in other European countries has been started successfully. With

more than 150 employees and customers in six countries, the company is also one of the largest providers on the market. The objective of this transaction is to develop solutions for existing and new customers further in an innovative way and additionally increase customer benefits thanks to product integration with NEXUS modules.

The transaction is expected to be concluded on 30 November 2018 (closing), and 100 % of the shares in the company will be transferred to NEXUS AG. We will also provide more information about the key economic figures at that time.

On the other hand, the acquisitions made in the second quarter have been implemented completely. NEXUS AG acquired 61 % of the shares of astraia software gmbh, Munich, at the beginning of June. The software of astraia supports gynecologists and obstetricians in ultrasound diagnostics and in carrying out and evaluating scientific studies. The company has approx. 30 employees in Munich. We also integrated modern customer relationship management (CRM) for hospitals and donation organizations in our software range with acquisition of 80 % of the shares of CREATIV SOFTWARE AG. CREATIV is the market leader

with more than 50 customers in Switzerland for CRM systems for non-profit and donation organizations and employs approx. 25 persons at its location in Widnau, Switzerland.

With the acquisitions and the upcoming integration of the products, we will close the last gaps in our product portfolio this year. This is an important step for us. This allows us to complete the phase of specialist product development. Today, NEXUS is positioned so that we can implement a fully digital hospital with all special applications from our own product portfolio. This gives us an exceptional position on the market.

In the future, we will be able to focus even more on product integration and regional expansion. There is still a lot to do and we still have significant improvement potential that we can and must realize.

Dear Shareholders, you see that we are also consistently pursuing our long-term goals in addition to healthy growth.

In addition to subject-related acquisitions, the core topics "European expansion" and "NEXT / NEXUS" are at the top of our priority list. We have to focus on these issues in the coming months and work on existing weaknesses in our organization. If this succeeds, we will be able to realize high growth rates in the future as well.

We want to thank you, dear Shareholders, for your trust.

Warm regards,



Dr. Ingo Behrendt
CEO



Financial Highlights

3RD QUARTER 2018 AND 2017

	30/09/2018	30/09/2017	Changes
	KEUR	KEUR	(in %)
Sales	95,943	86,282	11.2
Sales Healthcare Software	88,543	78,047	13.4
Sales Healthcare Service	7,400	8,235	-10.1
Domestic sales	51,787	47,228	9.7
Sales in foreign countries	44,156	39,054	13.1
Earnings before tax on income (EBT)	9,738	8,777	10.9
Earnings before interest and taxes on earnings (EBIT)	9,836	8,772	12.1
EBITA	12,507	10,699	16.9
EBITDA	18,725	16,101	16.3
Consolidated surplus	7,934	7,425	6.9
Cash Flow from current business transactions	20,215	19,856	1.8
Net income per share (undiluted/diluted) in EUR	0.50 / 0.50	0.46 / 0.46	8.7 / 8.7
Share price (closing price, XETRA) in EUR	26.40	25.96	1.7
Capitalization of software developments	3,000	3,749	-20.0
Depreciation	8,889	7,329	21.3
Acquisition-related depreciations from purchase price allocation	2,671	1,927	38.6
Fixed Assets (without deferred taxes)	117,395	94,781 ¹⁾	23.9
Current Assets / Short-Term Assets	53,101	54,643	-2.8
Net Liquidity	25,398	27,516	-7.7
Equity Capital	108,502	103,009 ¹⁾	5.3
Employees	1,135	960	18.2

1) out-off date 31 December 2017

Interim Report

REPORT ABOUT THE PROFIT, FINANCIAL AND ASSET SITUATION

NEXUS Group sales increased from KEUR 86,282 to KEUR 95,943 (+11.2 %) in the first nine months of the year 2018.

As a result, the sustained steady good sales development of the NEXUS Group of recent years could be continued in the first nine months of 2018. Sales increased from KEUR 78,047 to KEUR 88,543 (+13.4 %) in the Healthcare Software Division. In the Healthcare Service Division, sales of KEUR 7,400 (9M-2017: KEUR 8,235) were achieved. Project delays have occurred in this division, which have been reflected in sales.

We were able to increase sales in Germany by 9.7 % to KEUR 51,787 (9M-2017: KEUR 47,228). In international business, we recorded sales of KEUR 44,156 from January to September 2018 compared to KEUR 39,054 (9M-2017) (+13.1 %). The increase was achieved despite the development of the Swiss franc. The average exchange rate of the Swiss franc was at SFR 1.16 on 30 September 2018 and consequently above the average price on 31 December 2017 (SFR 1.11), resulting in a reduction of KEUR 913 in sales and KEUR 96 in earnings. Sales include the figures of the companies acquired and consolidated in the 2018 financial year. Without the company acquisitions, the increase in sales would have been approx. 4.5 % lower in 2018 and would have equaled 6.7 %

The result before taxes and interest (EBIT) developed positively. KEUR 9,836 (9M-2018) were recorded and consequently an increase of 12.1 % compared to the previous year (9M-2017: KEUR 8,772). A value of KEUR 12,507 was achieved in EBITA and consequently was 16.9 % above the value of previous year (9M-2017: KEUR 10,699). EBITDA increased considerably compared to the previous year to 16.3 % (9M-2018: KEUR 18,725, 9M-2017: KEUR 16,101).

In the reporting period, cash flow from operating activities reached a value of KEUR 20,215 compared to the very strong prior-year period (9M-2017: KEUR 19,856).

The consolidated surplus increased by 6.9 % from KEUR 7,425 (9M-2017) to KEUR 7,934. Earnings per share were EUR 0.50 (9M-2017: EUR 0.46).


Cash and cash equivalents including securities amounted to KEUR 25,398 on 30 September 2018 (30 September 2017: KEUR 27,516).

Investments in tangible and intangible assets were made in the amount of KEUR 6,471 in the first nine months of 2018 (9M-2017: KEUR 6,183). This includes KEUR 3,000 (9M-2017: KEUR 3,749) for capitalizing software developments.

The balance sheet total increased from KEUR 151,279 to KEUR 172,067 (30 September 2018) compared to 31 December 2017. There are no essential bank liabilities. Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 100,237 following KEUR 81,051 (31 December 2017). Receivables from customers increased slightly from KEUR 21,389 (30 September 2017) to KEUR 22,685 (30 September 2018).


Group Earnings before Interest and Taxes (9 months) in KEUR

+12.1 % compared to previous year



EBITA (9 months) in KEUR

+16.9 % compared to previous year



Employees

On 30 September 2018 NEXUS Group employed a total of 1,135 employees (30 September 2017: 960 employees).

Effect of applying IFRS 15 as of 01 January 2018

At the date of conversion on 01 January 2018, NEXUS Group applied the modified retrospective method to contracts not yet completed. From the conversion within the context of IFRS 15, the revenue reserve of the NEXUS Group increased by approx. KEUR 202.

Structure changes of subsidiary companies

The following structure changes were implemented:

- + NEXUS / INOVIT GmbH, Ismaning, was merged with the merger agreement of November 20, 2017 into NEXUS / DIS GmbH, Frankfurt/Main, on 1 January 2018.
- + NEXUS AG acquired 55.0 % of the shares of MedHub sp. z o.o., Posen, on 9 January 2018.
- + NEXUS AG purchased the remaining 4.5 % of the shares from the existing option agreement of the subsidiary Marabu EDV-Beratung und -Service GmbH, Berlin, on 28 March 2018.
- + NEXUS AG purchased the remaining 49.0 % of the shares in the already existing subsidiary ProLohn GmbH, Singen, on 23 April 2018.
- + ProLohn GmbH, Singen, were merged with the merger agreement dated 8 May 2018 into nexus / switspot GmbH, Neckarsulm, as of 1 January 2018.
- + With the assignment agreement dated 9 May 2018, NEXUS Medizinsoftware und Systeme AG, Altishofen, ceded all shares in NEXUS Schweiz GmbH, Altishofen, as of 1 January 2018 to Domis Consulting AG, Altishofen.
- + NEXUS Schweiz GmbH, Altishofen, as well as syseca informatik ag, Altishofen, were merged with the merger agreement dated 4 June 2018 into Domis Consulting AG, Altishofen, as of 1 January 2018. Domis Consulting AG, Altishofen, was renamed NEXUS Schweiz AG, Altishofen, on 21 June 2018.
- + NEXUS AG acquired 61.0 % of the shares of ASTRAIA Software GmbH, Munich, as of 5 June 2018.
- + NEXUS AG acquired 80.0 % of the shares of Creativ Software AG, Widnau, on 13 June 2018.

Annual Stockholders Meeting and Dividends

At the Annual Stockholders Meeting of NEXUS AG in Donaueschingen on 27 April 2018, the Executive Board and Supervisory Board proposed to pay a one cent higher dividend of EUR 0.16 to shareholders than the previous year from the retained earnings of fiscal year 2017. The proposal was adopted by the required majority. Consequently, there was a total distribution of KEUR 2,519 on 03 May 2018.

Financial Highlights 9 months 2018

- + 11.2 % increase in sales from KEUR 86,282 (9M-2017) to KEUR 95,943 (9M-2018)
- + 12.1 % increase of EBIT from KEUR 8,772 (9M-2017) to KEUR 9,836 (9M-2018)
- + High net liquidity of KEUR 25,398

Events after the Balance Sheet Date

NEXUS AG signed a purchase agreement on 11 October 2018 for the acquisition of Roche Diagnostics IT Solutions GmbH and the associated laboratory products „SWISSLAB Laboratory Information System“ and „LAURIS Order Communication System“. The objective of this transaction is to develop solutions for existing and new customers further in an innovative way and additionally increase customer benefits thanks to product integration. Conclusion of the transaction is planned for 30 November 2018 (closing). The first-time consolidation into the Group will take place from 1 December 2018.

Accounting and Valuation Methods

This interim report from the NEXUS Group of 30 September 2018 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 30 September 2018. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2017. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2017.

The report has not been audited.

The Annual Report 2017 and Quarterly Report as of 30 September 2018 could be downloaded on www.nexus-ag.de.

SALES BY REGION

	01/01- 30/09/18	01/01- 30/09/17	Changes	01/07- 30/09/18	01/07- 30/09/17	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Germany	51,787	47,228	9.7	16,886	16,605	1.7
Switzerland	21,253	21,201	0.2	7,128	6,326	12.7
Netherlands	10,345	10,170	1.7	3,458	3,077	12.4
France	4,114	3,881	6.0	1,272	1,213	4.9
Austria	1,591	1,471	8.2	144	299	-51.8
Other countries	6,853	2,331	194.0	2,609	632	312.8
TOTAL	95,943	86,282	11.2	31,497	28,152	11.9

SALES BY DEVISION

	01/01- 30/09/18	01/01- 30/09/17	Changes	01/07- 30/09/18	01/07- 30/09/17	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Healthcare Software	88,543	78,047	13.4	29,245	25,602	14.2
Healthcare Service	7,400	8,235	-10.1	2,252	2,550	-11.7
TOTAL	95,943	86,282	11.2	31,497	28,152	11.9

Capital market, event and finance data

INVESTOR RELATIONS

Active communication with our stockholders, potential investors, analysts and the finance market are the focal point of our investor relation activities. We continually inform all market participants promptly and comprehensively via press releases and ad hoc announcements as well as the mandatory quarterly, semi-annual and annual financial reports.

In addition, we cultivate intensive dialog with institutional investors and finance analysts via one-on-one meetings and on roadshows. Our Investor Relations team is of course at your disposal as contact persons.

Frankfurt Stock Exchange stock prices (1-year period)



Stock Market Highlights (XETRA closing prices)

- + Initial listing
on 02 January 2018: 26.30 €
- + Highest price
on 16 January 2018: 30.20 €
- + Closing price
on 28 September 2018: 26.40 €
- + Stock market capitalization
on 28 September 2018:
415.9 million €

06-07 November 2018

INUG-Jahrestagung, Berlin

09 November 2018

QM-Praxis-Tag, Hannover

23 November 2018

Mobile Health Congres & iZone,
Netherlands

17-19 January 2019

CT Symposium,
Garmisch-Partenkirchen

24-27 January 2019

Bamberger Morphologietage

09-11 April 2019

DMEA, Berlin

06 November 2018

Quarterly Report Q3 / 2018

26-28 November 2018

Analyst Event, Frankfurt

05 March 2019

Annual Report 2018

Unternehmensinfor- mationen und Ausblick

Chances and Risks Report

Please refer to the explanations in the annual report of 31 December 2017 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

Director's Holdings

The director's holders of the Supervisory Board and the Executive Board are as follows on 30 September 2018 in comparison to the previous year: cf. Table.

Supervisory Board	Numbers of stock owned (Previous Year)	Numbers of options (Previous Year)
Dr. jur. Hans-Joachim König	69.900 (89.900)	0 (0)
Prof. Dr. Alexander Pocsay	121.500 (121.500)	0 (0)
Prof. Dr. Ulrich Krystek	0 (0)	0 (0)
Wolfgang Dörflinger	0 (0)	0 (0)
Gerald Glasauer	0 (0)	0 (0)
Prof. Dr. med Felicia M. Rosenthal	520 (315)	0 (0)

Executive Board	Numbers of stock owned (Previous Year)	Numbers of options (Previous Year)
Dr. Ingo Behrendt	111.900 (111.900)	0 (0)
Ralf Heilig	127.650 (137.650)	0 (0)
Edgar Kuner	240.351 (250.351)	0 (0)

Outlook: One NEXUS!

The first nine months of 2018 have again been extremely positive. An increase in sales of approx. 11 % and a rise in EBITA of around 17 % as well as a high operating cash flow of approx. EUR 20 million are excellent results. We were able to continue the positive development of the past years unabated.

In addition, independent of the strong growth of previous years, we also implemented a whole series of strategic projects this year. Of particular importance is the signed agreement to acquire Roche Diagnostics IT Solutions GmbH, with which we are integrating a leading European laboratory system into our company and our product portfolio. We can now offer our customers the full range of specialized e-health solutions, and consequently a digital hospital from a single source. This is a unique market position.

This makes it all the more important for us to present a product and technology-unified product base to the market that can also be easily integrated internationally. With our NEXT / NEXUS strategy, we have already taken care of many topics and are also on the right track in terms of internationalization. However, in coordinating our solutions as well as in our organization and service orientation, many topics still must be dealt with and we urgently need to address them.

Therefore, we are going to start a new change program in the next few months, which will run under the term „One NEXUS“. In this program, we want to accelerate the organizational and technological convergence of NEXUS and make it even more effective on the market.

Dear Shareholders, The NEXUS team is facing these challenges enthusiastically and thanks you for your confidence.



„Every operation requires your full concentration. We ensure that you do not have to worry about sterile instruments.“

NEXUS – MEDICINE IN FOCUS

Group profit and loss account

**FOR THE PERIOD FROM 01 JANUARY TO
30 SEPTEMBER 2018 AND 2017**

	01/01- 30/09/2018	01/01- 30/09/2017	01/07- 30/09/2018	01/07- 30/09/2017
	KEUR	KEUR	KEUR	KEUR
Revenue	95,943	86,282	31,497	28,153
Development work capitalized	3,000	3,749	739	1,009
Other operating income	3,490	1,854	2,111	659
Cost of materials including purchased services	15,280	14,677	5,039	4,220
Personnel costs	55,773	50,760	18,336	16,797
Depreciation	8,889	7,329	3,218	2,370
Other operating expenses	12,655	10,347	4,523	3,549
OPERATING RESULT	9,836	8,772	3,231	2,885
Finance Income	36	70	1	8
Finance Expenses	134	65	42	7
RESULT BEFORE TAX ON PROFIT	9,738	8,777	3,190	2,886
Taxes on profit	1,804	1,352	468	442
CONSOLIDATED SURPLUS	7,934	7,425	2,722	2,444
Of the consolidated surplus, accounted to:				
- Stockholders of NEXUS AG	7,865	7,197	2,836	2,441
- Shares of non-controlling partners	69	228	-144	3
CONSOLIDATED NET EARNINGS PER SHARE IN EUR				
Weighted average (undiluted/diluted) of issued shares in circulation (in thousands)	15.733 / 15.733	15.734 / 15.785	15.733 / 15.733	15.734 / 15.785
Undiluted / diluted	0.50 / 0.50	0.46 / 0.46	0.18 / 0.18	0.16 / 0.16

Group Statement of Consolidated Income

**FOR THE PERIOD FROM 01 JANUARY TO
30 SEPTEMBER 2018 AND 2017**

	01/01- 30/09/2018	01/01- 30/09/2017	01/07- 30/09/2018	01/07- 30/09/2017
	KEUR	KEUR	KEUR	KEUR
Consolidated surplus	7,934	7,425	2,722	2,444
Actuarial profits and losses	1,505	477	0	-4
Tax effects	-186	-179	0	-50
Currency conversion differences	-617	-831	226	1,058
OTHER OVERALL RESULT	702	-533	226	1,004
OVERALL RESULT OF THE PERIOD	8,638	6,892	2,948	3,448
Of the overall result of the period, accounted to:				
- Stockholders of NEXUS AG	8,572	6,674	3,067	3,371
- Shares of non-controlling partners	64	218	-119	77

Consolidated Balance Sheet

AS OF 30 SEPTEMBER 2018 AND 31 DECEMBER 2017

ASSETS	30/09/2018	31/12/2017
	KEUR	KEUR
LONG-TERM ASSETS		
Goodwill	67,618	49,314
Other intangible assets	37,266	35,804
Fixed (Intangible) assets	10,883	9,407
Shares in companies valued at equity	31	31
Deferred tax assets	1,571	2,169
Other financial assets	1,597	225
Total of Long-Term Assets	118,966	96,950
SHORT-TERM ASSETS		
Inventories	778	574
Trade receivables and other receivables	22,685	21,686
Receivables from tax on profits	694	783
Other non-financial assets	2,392	2,196
Other financial assets	1,154	705
Short-term financial assets	1,646	1,849
Cash and balance in bank	23,752	26,536
Total of Short-Term Assets	53,101	54,329
Balance Sheet Total	172,067	151,279

EQUITY AND LIABILITIES	30/09/2018	31/12/2017
	KEUR	KEUR
EQUITY CAPITAL		
Subscribed capital	15,752	15,752
Capital reserves	34,166	34,953
Retained earnings	55,515	48,202
Consolidated surplus	7,865	9,832
Other cumulated Group result	-5,497	-6,204
Own shares	-229	-419
EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY	107,572	102,116
Shares of non-controlling partners	930	893
Total Equity Capital	108,502	103,009
LONG-TERM DEBTS		
Pension obligations	10,336	10,515
Deferred tax liabilities	6,118	6,236
Other financial debts	15,812	5,148
Total of Long-Term Debts	32,266	21,899
SHORT-TERM DEBTS		
Accruals	2,006	2,240
Financial liabilities	4,605	5,607
Liabilities from tax on profit	1,973	1,126
Deferred revenue	10,173	2,391
Other non-financial debts	6,304	7,625
Other financial debts	6,238	7,382
Total of Short-Term Debts	31,299	26,371
Balance Sheet Total	172,067	151,279

Consolidated Cash Flow Statement

**FOR THE PERIOD FROM 01 JANUARY TO
30 SEPTEMBER 2018 AND 2017**

	2018	2017
	KEUR	KEUR
1. CASH FLOW FROM CURRENT BUSINESS TRANSACTIONS		
Group annual result before tax on income	9,738	8,777
Write-offs (+) / write-ups (-) on intangible assets, tangible assets and financial assets	8,889	7,329
Other expenses not affecting payment (+) / revenue (-)	1,001	308
Increase (-) / decrease (+) in inventories	-118	390
Gain (-) / loss (+) on disposal of fixed assets and securities	261	180
Increase (-) / decrease (+) in receivables and other assets from operating activities	2,183	-1,532
Increase (+) / decrease (-) of accruals insofar as not entered in other comprehensive income	-1,346	-590
Increase (+) / decrease (-) in liabilities from operating activities	1,216	6,440
Paid interest (-)	-76	-25
Received interest (+)	36	70
Taxes on profit paid (-)	-2,048	-1,546
Taxes on profit received (+)	479	55
	20,215	19,856
2. CASH FLOW FROM INVESTMENT ACTIVITIES		
Payments (-) for investments in intangible and fixed assets	-6,471	-6,183
Payments (-) for the acquisition of companies consolidated minus cash acquired	-11,769	-3,084
Payments (-) / receipts (+) from the acquisition/disposal of short-term financial assets	203	1,000
	-18,037	-8,267
3. CASH FLOW FROM FINANCIAL ACTIVITIES		
Dividends paid (-)	-2,519	-2,358
Payments (-) for the acquisition of own shares	-804	-50
Payments (-) for the (future) acquisition of non-controlling interests in already consolidated companies	-1,537	0
Receipts (+) from the sales of own shares	177	21
	-4,683	-2,387
Cash relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	-2,505	9,202
Exchange rate changes on cash and cash equivalents	-279	488
Cash and cash equivalents at beginning of period	26,536	15,923
Cash and cash equivalents at end of period	23,752	25,573
COMPOSITION OF CASH AND CASH EQUIVALENTS		
Liquid funds	23,752	25,573
	23,752	25,573

Group Statement of Changes in Equity

AS OF 30 SEPTEMBER 2018 AND 30 SEPTEMBER 2017

	Subscribed capital	Capital reserves	Retained earnings	Annual Net Profit	Equity capital difference from currency conversion	Pension reserves	Own shares	Equity capital attributable to stock of parent company	Shares of non-controlling partners	Equity capital total	Authorized Capital
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
CONSOLIDATED EQUITY AS OF 01/01/2017	15,736	34,307	42,414	8,146	2,827	-7,582	-244	95,604	198	95,802	3,000
Posting of consolidated surplus 2016 in the Group profit carried forward			8,146	-8,146				0		0	
Actuarial profits and losses						471		471	6	477	
Deferred taxes entered in other comprehensive income						-178		-178	-2	-179	
Currency differences			618		-1,325	-110		-817	-14	-831	
OTHER COMPREHENSIVE INCOME AFTER TAXES AS OF 30/09/2017	0	0	618	0	-1,325	184	0	-523	-10	-534	0
Consolidated surplus 9M-2017				7,197				7,197	288	7,485	
OVERALL RESULT OF THE PERIOD	0	0	618	7,197	-1,325	184	0	6,674	218	6,951	0
Dividend payment			-2,358					-2,358		-2,358	
Purchase of own shares		-47					-3	-50		-50	
Sale of own shares		20					1	21		21	
New minority interests								0	40	40	
Stock-Based Payment		395						395		395	
CONSOLIDATED EQUITY AS OF 30/09/2017	15,736	34,675	48,820	7,197	1,502	-7,398	-246	100,286	456	100,742	3,000

	Subscribed capital	Capital reserves	Retained earnings	Annual Net Profit	Equity capital difference from currency conversion	Pension reserves	Own shares	Equity capital attributable to stock of parent company	Shares of non-controlling partners	Equity capital total	Authorized Capital
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
CONSOLIDATED EQUITY AS OF 01/01/2018	15,752	34,953	48,202	9,832	889	-7,093	-419	102,116	893	103,009	2,984
Posting of consolidated surplus 2017 in the Group profit carried forward			9,832	-9,832				0		0	
Actuarial profits and losses						1,501		1,501	4	1,505	
Deferred taxes entered in other comprehensive income						-185		-185	-1	-186	
Currency differences				0	-10	-599		-609	-8	-617	
OTHER COMPREHENSIVE INCOME AFTER TAXES AS OF 30/09/2018	0	0	0	0	-10	717	0	707	-5	702	0
Consolidated surplus 9M-2018				7,865				7,865	69	7,934	
OVERALL RESULT OF THE PERIOD	0	0	0	7,865	-10	717	0	8,572	64	8,636	0
Dividend payment			-2,519					-2,519		-2,519	
Purchase of own shares							-804	-804		-804	
Stock-Based Payment		-787					817	30		30	
New minority interests								0	-27	-27	
Sale of own shares							177	177		177	
CONSOLIDATED EQUITY AS OF 30/09/2018	15,752	34,166	55,515	7,865	879	-6,376	-229	107,572	930	108,502	2,984

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 06 November 2018

NEXUS AG
The Executive Board

nexus/ag

NEXUS AG, Irmastraße 1, D-78166 Donaueschingen
Tel. +49 771 22960-0, Fax +49 771 22960-226
www.nexus-ag.de, ir@nexus-ag.de